A 12-Month Noninterventional, Postmarketing, Multicenter Study to Evaluate the Effectiveness of Briviact (Brivaracetam) as Adjunctive Therapy in Patients With Epilepsy With Partial-Onset Seizures in Daily Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 03 Jun 2018
At a glance
- Drugs Brivaracetam (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Acronyms BASE
- Sponsors UCB; UCB Biopharma
- 03 Jan 2018 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
- 03 Jan 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2019.
- 25 Feb 2016 New trial record